The companies said Monday that the agreement, unanimously approved by both companies' boards, will leave Decoy investors with about 86% ownership of the outstanding shares of the combined company.

Salarius Pharmaceuticals (SLRX) and Decoy Therapeutics announce the signing of a definitive agreement under which Decoy Therapeutics will merge ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and therefore flagged by the Incapsula network. Incapsula displays this page for ...

The newly formed company will be named Decoy Therapeutics. This proposed transaction is expected to facilitate multiple value-creating inflection points with Decoy’s pipeline of peptide ...

Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence ...